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Abstract
Correct classification of breast cancer sub-types is of high impor-
tance as it directly affects the therapeutic options. We focus on triple-
negative breast cancer (TNBC) which has the worst prognosis among
breast cancer types. Using cutting edge methods from the field of
robust statistics, we analyze Breast Invasive Carcinoma (BRCA) tran-
scriptomic data publicly available from The Cancer Genome Atlas
(TCGA) data portal. Our analysis identifies statistical outliers that
may correspond to misdiagnosed patients. Furthermore, it is illus-
trated that classical statistical methods may fail in the presence of
these outliers, prompting the need for robust statistics. Using robust
sparse logistic regression we obtain 36 relevant genes, of which ca.
60% have been previously reported as biologically relevant to TNBC,
reinforcing the validity of the method. The remaining 14 genes iden-
tified are new potential biomarkers for TNBC. Out of these, JAM3,
SFT2D2 and PAPSS1 were previously associated to breast tumors or
other types of cancer. The relevance of these genes is confirmed by
the new DetectDeviatingCells (DDC) outlier detection technique. A
comparison of gene networks on the selected genes showed significant
differences between TNBC and non-TNBC data. The individual role
of FOXA1 in TNBC and non-TNBC, and the strong FOXA1 -AGR2
connection in TNBC stand out. Not only will our results contribute
to the breast cancer/TNBC understanding and ultimately its man-
agement, they also show that robust regression and outlier detection
∗The first two authors contributed equally to this work.
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constitute key strategies to cope with high-dimensional clinical data
such as omics data.
1 Introduction
Triple-negative breast cancer (TNBC) represents 10% to 17% of all diag-
nosed breast tumors [1], and has the worst prognosis amongst the different
sub-types of breast cancer (BC) [2]. TNBC is characterized by the lack
of expression of targetable genes like estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor receptor 2 (HER2) [3].
Based on this, the current standard of care treatment protocols for TNBC
are limited to surgery, radiotherapy and chemotherapy [4]. Since the BC
sub-type directly influences the therapeutic options, there is a high demand
for the development of methods that not only accurately classify BC patients
into BC sub-types, but also identify relevant (target) genes that discriminate
between TNBC patients and patients with other types of BC. The identifica-
tion of genes that are either down- or up-regulated in TNBC is expected to
play an important role in precision medicine, by providing a more in-depth
knowledge on the cancer biology, but also yielding diagnostic, prognostic,
and therapeutic markers that will ultimately improve patient outcomes [5].
The classification of BC into TNBC and non-TNBC is dependent on
the presence of ER, PR and HER2 receptors, either ‘positive’ or ‘negative’,
based on the results obtained by immunohistochemical (IHC) and fluores-
cence in-situ hybridization (FISH) testing technologies. However, prean-
alytic variables, thresholds for positivity, and interpretation criteria may
generate inaccurate results. For example, it has been reported that up to
20% of ER and PR test results are false negative or false positive [6]. The
clinical consequences are extremely important. A patient given a wrong BC
subtype classification will undergo inappropriate cancer treatment, either
hormonal based or not, with severe consequences for cancer progression and
survival. False negatives for ER and PR will not benefit from endocrine
therapy, and for false positives the hormonal therapy will fail. On the other
hand, while a false positive HER2 assessment leads to the administration
of potentially toxic, costly and ineffective HER2-targeted therapy, a false
negative HER2 assessment results in denial of anti-HER2 targeted therapy
for a patient who could benefit from it [7].
In this context, statistical analysis of gene expression data for known BC
cases may provide valuable insights. However, real data often contain one
or more observations deviating from the main pattern of the data [8, 9]. For
example, when considering gene expressions from TNBC data, inaccuracies
may be due to variations in ER, PR and HER2 testing, as mentioned above.
Wrong TNBC class labels may result from inconsistencies between the IHC
and FISH testing technologies. Unfortunately, classical results are heavily
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influenced by these suspicious observations. The effect of outliers may be
such that classical statistical techniques no longer detect them. This phe-
nomenon is known as masking in statistics literature [10]. Moreover, outly-
ing observations may even influence classical statistics so much that regular
observations are flagged as outliers, a phenomenon known as swamping (see
e.g. [11]). In regression models, these observations may compromise the
predictive performance. Due to the high dimensional nature of the data,
typical regression techniques are no longer valid. For example, the classi-
cal least squares fit cannot be computed when there are fewer observations
than variables. Therefore, one uses sparsity-inducing methods to select rele-
vant subsets of the original variables. However, these sparse methods might
also be impacted by outliers, leading to relevant variables being neglected
and irrelevant variables being selected[12]. Moreover, detecting interesting
anomalous cases (e.g., a normal patient with deviating expressions of specific
genes) may be of particular interest.
The importance of detecting outlying patients is therefore twofold. Out-
liers corresponding to errors in the labeling must be detected and treated
accordingly in order to achieve accurate model predictions. Correctly di-
agnosing patients is of utmost interest as wrongly diagnosed patients may
receive ineffective, expensive and potentially harmful treatment. Secondly,
outliers which are not errors reveal hidden information on the covariates
that might play a role in the definition of new therapies based on target
genes revealed by outlier analysis.
The remainder of the paper is structured as follows. In the next section
we dicuss TNBC data construction from RNA-Seq and clinical data from
Breast Invasive Carcinoma (BRCA). We then discuss logistic regression as
a tool to decide BC class membership. Due to the high dimensionality of
the data and the concern for outliers, we then turn to robust sparse logistic
regression which selects relevant variables and flags outlying cases. Also
the DetectDeviatingCells (DDC) method [13] is applied, and its results are
linked to those of the robust logistic regression which brings new insights.
The paper concludes with a discussion of results and model diagnostics along
with the biological interpretation of the selected gene set.
2 Data description
The BRCA data set is publicly available from the Cancer Genome Atlas
(TCGA) Data Portal [14] and contains genomic and clinical data from breast
cancer (BC) patients. The RNA-Seq Fragments Per Kilo base per Million
(FPKM) data was imported using the ‘brca.data’ R package [15]. The BRCA
gene expression data is composed of 57251 variables for a total of 1222
samples from 1097 individuals. From those samples, 1102 correspond to
primary solid tumor, 7 to metastases and 113 to normal breast tissue. Only
3
samples from primary solid tumor were considered for analysis.
The TNBC gene expression data set was built based on the BRCA RNA-
Seq data set available from TCGA. A subset of 19688 variables, including the
three TNBC-associated genes ER (ENSG00000091831), PR (ENSG00000082175)
and HER2 (ENSG00000141736), was considered, corresponding to the pro-
tein coding genes reported from the Ensemble genome browser [16] and the
Consensus CDS [17] project. The response variable Y , corresponding to
the clinical type, is a binary vector coded with ‘1’ for TNBC individuals
and ‘0’ for non-TNBC. This vector was built based on the BRCA clinical
data available from TCGA, regarding the individuals’ label for ER, PR and
HER2 (either ‘positive’,‘negative’ or ‘indeterminate’). When a ‘negative’ la-
bel is recorded for all three genes the response is set to ‘1’ (TNBC), whereas
in all other cases the status is ‘0’ (non-TNBC). However, for assessing the
HER2 label, three variables are available from the clinical data: two from
the IHC analysis, the HER2 level and status, and another corresponding to
the HER2 status obtained by FISH. The IHC status was considered, since
it was measured for a larger number of individuals. Whenever both IHC
status and FISH status were available for a given patient, the FISH sta-
tus was considered instead, as FISH is a more accurate test for classifying
individuals into HER2 ‘positive’ or ‘negative’.
A total number of 28 individuals were marked as suspect when no con-
cordance existed between the HER2 IHC level and status, and between the
HER2 IHC status and FISH status. Special attention will be given to indi-
viduals for which non-concordance between lab testing exists and the choice
of one or another determines the final label (TNBC vs. non-TNBC). These
suspect individuals are potentially mislabeled, therefore potential outliers.
We will verify whether they belong to the list of outlying individuals detected
in this study. The variables age and race were also included as explanatory
variables, since they were statistically significant in separate univariate lo-
gistic regressions to predict the individuals’ status.
3 Methods
Let X ∈ Rn×p denote the matrix of the predictors and Y ∈ Rn×1 the
response vector. The logistic model may be formalized as
Y = pi(X) + ε
with
pi(X) =
exp (Xβ)
1 + exp (Xβ)
and β = (β1, . . . , βp)
t the vector of length p containing the regression coef-
ficients and n the sample size.
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Typically, the regression coefficients β are estimated using the maximum
likelihood estimator which minimizes the negative log-likelihood function:
βˆML = argmin
β
n∑
i=1
d(xi, yi;β)
where the deviance is d(xi, yi;β) = log
(
1 + exp
(
xtiβ
))
− yix
t
iβ.
However, when the number of variables p is large, standard maximum
likelihood estimators can be very difficult to interpret. Also the predictive
power of a model may be impacted when including too many variables [18,
19]. Moreover, when p > n the maximum likelihood estimator cannot even
be computed. A possible solution to this problem is to consider so-called
shrinkage estimators (for a review see e.g. Tibshirani, 2011[20]). For these
estimators, a penalty term on the regression coefficients is included in the
objective function. In the next section we will discuss several shrinkage
estimators.
3.1 Sparse logistic regression
One of the first shrinkage estimators in the literature is ridge regression
[21, 22]. The estimator for β then becomes the vector βˆridge minimizing
n∑
i=1
d(xti, yi;β) + λ||p
t · β||22 =
n∑
i=1
d(xti, yi;β) + nλ
p∑
j=1
(pjβj)
2 .
Here · stands for the elementwise product. The tuning parameter λ > 0
controls the severity of the penalty and thus the level of shrinkage. A higher
value of λ will lead to a higher importance of the penalty and thus a higher
percentage of coefficients pulled towards zero. The vector p is a vector
containing penalty factors that control how much of the penalty λ affects
each coefficient. If the j-th component of p is zero, the coefficient βj is not
penalized. On the other hand if pj = 1, βj the full penalty λ is applied to
βj .
A downside of ridge regression is that it cannot shrink coefficients exactly
to zero. Ridge regression will keep all the variables in the model [18, 19, 23].
The LASSO estimator [19], which employs an l1 penalty instead of the l2,
may be used to solve this problem. It performs variable shrinkage and
variable selection at the same time. The LASSO-estimate of β is the vector
βˆLASSO minimizing
n∑
i=1
d(xti, yi;β) + λ||p · β||1 =
n∑
i=1
d(xti, yi;β) + λ
p∑
j=1
|pjβj |.
Again the tuning parameter λ > 0 controls the sparsity of the resulting co-
efficients. A downside of the LASSO estimator is that it tends to radomly
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select only one variable in a group of highly correlated variables while dis-
carding the other variables [24].
The elastic net procedure proposed by Zou and Hastie (2005)[24] tries to
overcome the downsides of both ridge regression and the LASSO. It shrinks
the variables and performs variable selection while being able to select groups
of correlated variables. The sparse estimate for β then becomes the vector
βˆenet minimizing
n∑
i=1
d(xti, yi;β) + nλ
[
(1− α)
||p · β||22
2
+ α||p · β||1
]
.
The parameter α controls the mixing between the ridge and LASSO penalty
and should be chosen in the interval [0, 1]. Clearly, when α = 0 the ridge
estimator is obtained, whereas for α = 1 the LASSO estimate is recovered.
The optimal values for λ and α may be obtained using k-fold cross-validation
techniques. Software implementations of the elastic net method can be found
in the free R software [25] package glmnet [26].
In the next subsection we discuss how the elastic net procedure may be
modified to make it robust to outliers. We will first discuss a robustification
of the non-sparse maximum likelihood technique before turning our attention
a robust sparse procedure.
3.2 Robust sparse logistic regression
The maximum likelihood estimator is highly susceptible to outliers, because
both outliers in the predictor space and outliers in the response variable may
have an unbounded effect on the log-likelihood. As a possible alternative,
more robust procedures have been proposed. For an outlier-contaminated
data set they provide a solution that is close to the one that would be
obtained on an outlier-free data set using classical methods. One of the
ways to achieve robustness is to use a trimmed log-likelihood function. For
linear regression the resulting estimator is called the Least Trimmed Squares
(LTS) estimator [27, 28].
For logistic regression the LTS estimator is defined by
βˆLTS = argmin
β
h∑
i=1
d(xti, yi;β)i:n
where the subscript i : n indicates the i-th smallest deviance, i.e. the n
deviances are first sorted from smallest to largest. The LTS thus minimizes
the trimmed deviance, for a subset of h data points out of the full sample
of size n. The number h is typically chosen between ⌊(n+ p+ 1)/2⌋ and n.
The choice of h determines the robustness of the LTS estimator. In practice
one frequently uses a conservative value of h as an initial choice. To improve
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efficiency one may then increase h to a higher value, while ensuring that h
stays below the number of non-outliers found in the data.
The ideas of LTS regression were adapted for sparse robust logistic re-
gression by Kurnaz and co-authors (2018) [29] and were implemented in
the R[25] software package enetLTS[30]. They defined the enet-LTS logis-
tic estimator which combines the sparsity of the elastic net procedure with
the robustness of LTS regression. In that sense their work is an extension
of sparse LTS regression [12] that combines the LTS estimator for linear
regression with the LASSO penalty. The enet-LTS estimator is defined by
βˆenet-LTS = argmin
β
(
h∑
i=1
d(xti, yi;β)i:n + hλ
[
(1− α)
||p · β||22
2
+ α||p · β||1
])
where λ ∈ [0, 1] as described for the glmnet penalty.
To increase efficiency, LTS regression usually includes a reweighting step
[8]. Generally speaking, the reweighting step identifies outliers according to
the above fitted robust LTS model. These are then downweighted before
fitting a classical model using these weights. Consider the Pearson residuals
rsi =
yi − pii(x)
pii(x)(1 − pii(x))
.
Under the logistic model these are known to be approximately normally
distributed. Each observation i then receives a weight wi of 1 when |r
s
i | < c
and 0 otherwise. The cutoff value c is determined as the 97.5 quantile of a
standard Gaussian distribution, so that 95% of the distribution lies between
−1.96 and 1.96 . The reweighted enet-LTS estimator is then defined as
argmin
β
(
n∑
i=1
wid(x
t
i, yi;β) + nwλ
[
(1− α)
||p · β||22
2
+ α||p · β||1
])
where nw =
∑
wi is the number of observations receiving weight one.
3.3 Detecting Deviating Data Cells
Let X ∈ Rn×p now denote a data matrix of sample size n and dimension
p. In statistics, an outlier typically refers to a row (case) that deviates from
the bulk of the data. However, it frequently occurs that such a row is only
suspicious for q out of the p variables, with q ≪ p [31, 32, 33, 34, 35].
Flagging the entire row as an outlier would thus be too conservative as the
remaining p−q measurements of that row still contain valuable information.
To work in this paradigm, we no longer see the data as n rows of p variables,
but rather as a data matrix of n × p cells. Cells with possibly deviating
behavior are then referred to as cellwise outliers.
Figure 1 illustrates these two different paradigms. The left panel indi-
cates three rowwise outliers in the data. The right panel identifies several
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contaminated cells in the data matrix. Even though many rows have one or
more outlying cells, they still contain valuable information in their remaining
cells.
n
1
1 d
Variables
O
b
je
c
ts
Rowwise
n
1
1 d
Variables
O
b
je
c
ts
Cellwise
Figure 1: Illustration of the cellwise outlier paradigm versus the typical
outlier paradigm.
In the context of the TNBC data, one may expect that TNBC patients
would only have deviating observations for a small subset of the full gene
expression data. We will therefore analyze the genes selected by the robust
sparse logistic regression using the DetectDeviatingCells (DDC) method re-
cently proposed by Rousseeuw and Van den Bossche (2018)[13]. This will
provide us with additional insight in the nature of flagged outliers and the
role of the selected genes.
The DetectDeviatingCells procedure uses bivariate correlations between
the different variables. It then computes a predicted value for each cell,
based on the values of other cells in the same row. Next, it compares the
predicted and observed value of each cell. When this robustly standardized
difference exceeds a certain cutoff, the cell is flagged. Cells for which the
observed value is much lower then the imputed value are colored blue. When
the observed value is higher than the imputed value, the cell is colored red.
4 Results and discussion
We analyzed the TNBC data set using both the sparse logistic and the
robust sparse logistic procedures discussed above. In both instances, the
parameters α and λ were selected using 5-fold cross-validation evaluating
the mean of the deviances in the fold. To eliminate randomness in the
selection of the folds, the cross-validation was averaged over 10 runs. For
the robust sparse logistic regression method, the parameter h was selected as
0.85n. This parameter was found to be a safe level guarding against outliers
after an initial run with h = 0.5n. The penalty factor p was chosen to be a
unity vector penalizing all coefficients equally, except for the coefficients of
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ER, PR and HER2 for which pj = 0.5 as these are of special interest in the
TNBC context.
Table 1 summarizes the sparse fits. For both procedures, we list the
selected α and λ parameters in the glmnet procedure and the resulting
number of non-zero coefficients. We also provide the number of observations
that are flagged as outliers with respect to the fitted model. The criterion
used to flag outliers in the classical sparse logistic model corresponds to
the procedure described in the reweighting step of the robust sparse logistic
regression method.
Table 1: Summary of the fitted models for the robust and non-robust sparse
logistic regression methods
sparse robust sparse
logistic regression logistic regression
α 1.00 0.81
λ 0.005 0.057
# of non-zero coefficients 136 36
Potential outliers 0 43
The results in Table 1 show that the cross-validation leads to different
parameter choices for α and λ between the robust and non-robust sparse
logistic regression method. The classical method selects roughly four times
as many coefficients (genes) as the robust method. Moreover, only three
of the 136 genes selected by the classical method are also selected by the
robust method, namely ER, HER2 and PPP1R14C. While the nonrobust
method fails to identify outlying observations, due to the masking effect
described in the introduction, the robust procedure indicates 43 observations
as potential outliers. It is important to note that all 43 outliers flagged by
the robust method are marked as non-TNBC patients in the data, but are
predicted to be TNBC according to the fitted model. If indeed true, these
patients would receive potentially toxic, costly and ineffective therapies. It
is therefore important to detect all such cases.
As neither model selects the variables age and race, the 95 observations
that were initially left out of the analysis due to missing values for either
of these variables may be used for out-of-sample testing. The prediction of
TNBC occurrence does not match with the data in 4 out of 95 cases for
the classical method and in 6 of the 95 cases for the robust method. Both
methods find two additional outliers in the test set corresponding to patients
who were attributed a non-TNBC status in the data. From the 6 cases who
did not match according to the robust method, two were borderline cases
with a predicted TNBC likelihood of 0.53 and 0.57 respectively. Even though
the robust model selects only a handful of genes compared to the classical
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method, its out of sample performance is comparable to traditional methods.
4.1 Detailed discussion of identified outliers
We now turn our attention to the observations flagged as potential outliers
by the robust method and and investigate how these observations differ from
the others. The expression of ER, PR and HER2 for the flagged outliers,
along with their label (TNBC vs. non-TNBC), can be found in Table 2.
All observations flagged as outliers are originally labeled non-TNBC in-
dividuals. From the list of 43 outliers detected, 7 were previously identified
as suspect, i.e., individuals for which there is no concordance between lab
methods for the HER2 determination (see Section Info on the Data). This is
particularly critical for individuals ER and PR ‘negative’ and for which the
HER2 label determines the final TNBC vs. non-TNBC label. For instance,
if the other HER2 (correct) testing result was chosen in individuals 12, 34
and 40, the final label would have been TNBC.
Several inconsistencies in labeling can be also observed for ER and PR
testing. An ER expression value of 0.03, for example, has corresponding
positive label for individual 8, while an ER value of 0.63 is translated into
a negative label for individual 11. Regarding PR labeling, the same PR
expression value of 0.03 corresponds to a negative label for individual 8
and to a positive label for individual 10. Similarly, individual 2 with a PR
expression value of 0.25 has a positive PR label, while individual 36 with a
PR expression value of 0.26 has a negative PR label. Besides uncertainty
in HER2 labeling with respect to the different testing, inconsistencies can
be also observed within a given test, e.g., the status by IHC. Individual
5 was labeled negative with a HER2 expression value of 15.1, and for the
same expression value individual 12 was labeled as HER2 positive. Wrong
labeling in one or more variables clearly impacts final labeling of individuals
into TNBC and non-TNBC, with serious consequences in clinical decision
and prognosis.
For other individuals, however, the outlyingness cannot be explained by
mislabeling of the three TNBC-associated gene expressions, as they seem to
have concordant gene expression and label (see e.g. individuals 9, 37 and 42).
This suggests that other genes than ER, PR and HER2 might contribute to
the discrimination between TNBC and non-TNBC individuals.
4.2 Discussion of selected genes with relation to outlier iden-
tification
To gain more insight we ran the DetectDeviatingCells (DDC) algorithm on
the 36 selected genes only, without telling DDC anything about the clinical
response variable or which rows were flagged as outliers. The result is a
cell map with over 1000 rows, which is hard to visualize. Therefore Figure
10
Table 2: Summary of the 43 individuals identified as outliers by robust sparse
logistic regression regarding ER, PR and HER2 gene expression and corre-
sponding clinical label (between brackets). Individuals highlighted in bold
correspond to individuals previously identified as suspicious as described
in the section ”Data description”. (We abbreviate fragments per kilobase
million by FPKM, indeterminate by Ind and equivocal by Equiv).
Genes
Individual ER PR HER2 Clinical type
FPKM FPKM FPKM (clinical)
(clinical) (clinical) level status status
IHC IHC FISH
1 TCGA-AR-A1AO 1.47(+) 1.13(-) 14.89 (-) (-) non-TNBC
2 TCGA-BH-A6R9 0.59(-) 0.25(+) 8.18 (-) non-TNBC
3 TCGA-AC-A62X 0.19(+) 0.02(-) 28.53 non-TNBC
4 TCGA-A2-A0YJ 0.09(+) 0.03(-) 240.24 (-) (-) non-TNBC
5 TCGA-LL-A5YP 0.16(+) 0.05(-) 15.10 (-) (-) (+) non-TNBC
6 TCGA-A7-A13D 0.52(-) 0.81(+) 42.28 (Ind) (Equiv) (-) non-TNBC
7 TCGA-E2-A1II 0.14(-) 0.19(+) 10.73 (-) (-) non-TNBC
8 TCGA-AR-A1AH 0.03(+) 0.03(-) 34.12 (-) non-TNBC
9 TCGA-BH-A0DL 6.99(+) 0.04(-) 9.92 (-) non-TNBC
10 TCGA-E2-A14Y 0.67(+) 0.03(+) 487.90 (Ind) (Equiv) (+) non-TNBC
11 TCGA-AO-A0JL 0.63(-) 0.08(-) 63.60 (-) (-) (+) non-TNBC
12 TCGA-AN-A0FL 0.09(-) 1.07(-) 15.07 (-) (+) non-TNBC
13 TCGA-AO-A1KO 10.78(+) 9.12(+) 14.91 (-) (-) non-TNBC
14 TCGA-AN-A0FX 1.13(-) 0.64(-) 24.02 (-) (+) non-TNBC
15 TCGA-A1-A0SB 3.16(+) 0.03(-) 32.35 (-) non-TNBC
16 TCGA-D8-A1JM 5.01(+) 0.01(-) 21.85 (-) (-) non-TNBC
17 TCGA-E9-A1NC 0.11(-) 0.08(+) 15.91 (+) non-TNBC
18 TCGA-A2-A25F 0.62(-) 0.23(+) 5.19 (-) non-TNBC
19 TCGA-A2-A1G1 0.53(-) 0.17(-) 819.76 (Ind) (Equiv) (+) non-TNBC
20 TCGA-LL-A6FR 0.33(-) 0.04(+) 32.13 (Ind) (Equiv) (+) non-TNBC
21 TCGA-A2-A3Y0 2.18(+) 0.03(-) 11.34 (-) (-) non-TNBC
22 TCGA-B6-A0IJ 1.18(+) 0.46(+) 11.12 non-TNBC
23 TCGA-AR-A0TP 0.04(+) 0.03(-) 13.39 (-) non-TNBC
24 TCGA-S3-AA0Z 16.67(+) 0.07(+) 33.07 (-) (Equiv) (-) non-TNBC
25 TCGA-A2-A4S1 0.29(+) 0.01(-) 0.61 (-) non-TNBC
26 TCGA-A7-A13E 0.82(+) 0.06(-) 46.08 (Ind) (Equiv) (-) non-TNBC
27 TCGA-D8-A1JK 0.40(-) 0.72(+) 22.19 (-) (-) non-TNBC
28 TCGA-E9-A1ND 1.44(-) 0.05(-) 13.05 (+) non-TNBC
29 TCGA-JL-A3YW 0.35(+) 0.09(+) 31.47 (-) (+) non-TNBC
30 TCGA-AN-A0FJ 0.08(+) 0.04(-) 14.28 (-) (+) non-TNBC
31 TCGA-D8-A1XW 0.32(-) 0.11(+) 21.03 (-) (-) non-TNBC
32 TCGA-UU-A93S 0.30(-) 0.12(-) 1668.35 (+) (+) non-TNBC
33 TCGA-OL-A5S0 0.09(+) 0.06(-) 31.92 (+) non-TNBC
34 TCGA-E9-A22G 0.44(-) 0.02(-) 15.32 (+) non-TNBC
35 TCGA-AR-A24Q 1.00(+) 0.36(-) 20.67 (-) non-TNBC
36 TCGA-E2-A1B0 0.14(-) 0.26(-) 563.81 (+) (+) non-TNBC
37 TCGA-AR-A251 1.57(+) 0.10(-) 14.02 (Ind) (Equiv) (-) non-TNBC
38 TCGA-A2-A4RX 0.68(+) 0.93(+) 26.64 (-) (-) non-TNBC
39 TCGA-AR-A1AJ 1.47(+) 0.07(-) 9.74 (-) non-TNBC
40 TCGA-A2-A04U 0.02(-) 0.02(-) 9.64 (-) (-) (+) non-TNBC
41 TCGA-BH-A5IZ 5.12(+) 0.03(-) 28.08 (-) (-) non-TNBC
42 TCGA-D8-A13Y 15.48(+) 4.17(+) 4.83 (-) (-) non-TNBC
43 TCGA-LL-A8F5 1.08(+) 0.04(-) 11.86 (-) (-) non-TNBC
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Figure 2: Cellwise outlier map. The columns correspond to the genes se-
lected by the robust sparse logistic model. The rows correspond to 30 non-
TNBC patients (label nT), 30 TNBC patients (label T) and the 43 outliers
found by the robust fit.
2 instead shows (from top to bottom) the first 30 non-TNBC patients, 30
TNBC patients, and the 43 outliers found by the robust logistic fit. The
indices of the outliers correspond to the row numbers in Table 2. A blue cell
in Figure 2 indicates an unexpectedly low gene expression value whereas a
red cell indicates an unexpectedly high value, relative to the other cells in its
row and using the correlations between the columns. We see that the overall
pattern detected by the DDC algorithm for the patients flagged as potential
outliers (all originally labeled as non-TNBC) matches the pattern observed
for the TNBC patients. This is a very strong indication that indeed these
patients have an erroneous label in the data.
Genes for which most of the cells of the TNBC patients are colored
are of particular interest. We may verify their predictive power for the
classification of TNBC patients by the size of the coefficients in the robust
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Figure 3: Interpretation of genes selected in the robust sparse logistic model.
The color coding corresponds to the color determined by the DDC map.
sparse logistic model. Figure 3 depicts the coefficient in the robust sparse
logistic model for each of the genes, using the same color coding as in the
DDC map. The coefficients of the ER, PR and HER2 gene receptors have
been colored black. We indeed see that the genes standing out in the DDC
map are mostly those genes with higher coefficients, in absolute value, in the
model. The red-colored genes turn out to get positive coefficients, the blue
genes get negative coefficients, and the yellow ones get coefficients closer to
zero. The selected genes may thus be of particular biological and medical
interest for the understanding and diagnosis of TNBC.
Table 3 lists the genes selected by the robust sparse logistic method. It
also includes the corresponding coefficients estimated by the robust sparse
logistic method, rounded to 3 digits. The color coding as determined by the
DDC map is also noted and corresponds to the color coding in Figure 3.
4.3 Biological interpretation of selected genes and correla-
tion structures
Among the 36 genes listed in Figure 3, 13 (36.1%) were down-regulated in
TNBC, and 23 (63.9%) were up-regulated. The majority of genes found to
be down-regulated in TNBC (11/13) were previously reported to be down-
regulated in this particular sub-type of BC, or overexpressed in ER+/HER2+
breast tumors. These include ESR1, PGR and HER2, but also AGR2 [36],
CA12 [37], FOXA1 [38], GATA3 [39, 40], MLPH [41, 42], SPDEF [43],
13
Table 3: Genes selected by the robust sparse logistic method, corresponding
coefficients (rounded to 3 digits) and their color coding. The genes are sorted
by their coefficient.
gene coef color gene coef color
0 Intercept 0.225 None 19 TMCC2 0.024 red
1 CT83 0.368 yellow 20 PAPSS1 0.021 yellow
2 FZD9 0.314 red 21 FANCE 0.020 yellow
3 SRSF12 0.297 red 22 TBC1D22B 0.018 yellow
4 ROPN1 0.260 red 23 SFT2D2 0.008 yellow
5 HORMAD1 0.252 red 24 GATA3 -0.021 blue
6 CHODL 0.215 red 25 SPARCL1 -0.030 yellow
7 POU5F1 0.134 yellow 26 PODN -0.044 yellow
8 VGLL1 0.125 red 27 TGFB3 -0.050 yellow
9 EN1 0.094 red 28 CA12 -0.051 blue
10 UGT8 0.088 red 29 PGR -0.053 yellow
11 ART3 0.083 red 30 AGR2 -0.072 blue
12 TMSB15A 0.077 red 31 JAM3 -0.080 yellow
13 B3GNT5 0.061 red 32 MLPH -0.097 blue
14 PPP1R14C 0.048 yellow 33 HER2 -0.246 yellow
15 TTLL4 0.041 yellow 34 SPDEF -0.338 blue
16 FOXC1 0.034 red 35 FOXA1 -0.441 blue
17 CDCA2 0.031 yellow 36 ESR1 -0.551 yellow
18 NKX1-2 0.025 yellow
SPARCL1 [44], and TGFB3 [45]. Also 11 of the 23 genes up-regulated in
TNBC were previously described as such, namely ART3 [46], B3GNT5 [47],
EN1 [48, 49], FOXC1 [50], FZD9 [51], HORMAD1 [52], POU5F1 [53],
ROPN1 [54], TMSB15A [55], UGT8 [56], and VGLL1 [57]).
Our analysis has led to the identification of 14 genes that were not
previously reported as specifically involved in TNBC or (breast) cancer
overall, therefore contributing to the search for new interest biomarkers to
further validate and functionally study. These include JAM3 and PODN,
down-regulated in TNBC; and SFT2D2, CDCA2, CHODL, CT83, FANCE,
NKX1-2, PPP1R14C, SRSF12, TBC1D22B, TMCC2, TTLL4, and PAPSS1,
up-regulated in TNBC. JAM3 has been previously identified as a biomarker
for cervical cancer [58]; and was found to be up-regulated and associated
with higher cancer risk in the offspring from mice with high fat diet intake
during pregnancy [59]. Amongst the up-regulated genes, SFT2D2 was pre-
viously described as down-regulated in a bone (specific) metastasis-related
gene set [60]. PAPSS1, involved in estrogen metabolism, was not directly
implicated in TNBC before but found to be overexpressed in breast tumor
tissues in comparison to adjacent normal tissue, independently of ER status
[61].
Finally, we consider a graphical representation of the correlation-based
network structure between the selected genes depicted in Figure 4. For clar-
ity, only correlations above 0.6 in absolute value are shown. The thickness
of the connecting lines represents the strength of the correlation, whereas
green represents a positive correlation and red signals a negative correlation.
Figure 4a shows the correlation plot for the non-TNBC individuals whereas
Figure 4b is the plot for TNBC individuals. The patterns in the left and
right panels are strikingly different.
The proto-oncogene AGR2 (anterior gradient homology 2) is among the
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Figure 4: Representation of the correlation between the genes selected by
the robust sparse logistic model. The color coding corresponds to the color
determined by the DDC map.
(a) Correlations for non-TNBC patients.
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(b) Correlations for TNBC patients.
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down-regulated genes in TNBC, and a strong correlation between AGR2 and
FOXA1 was found in TNBC. Moreover, AGR2 was correlated with other
genes, suggesting a particular relevance for this gene. AGR2 is a known
biomarker of poor prognosis in ER+ BC [62]. Accordingly, different studies
have reported that expression of the proto-oncogene AGR2 is induced by
estrogen and tamoxifen in BC cells [63]; and that AGR2 is required for the
growth and migration of ER+ cells. The transcription factor FOXA1 is im-
plicated in the regulation of many ERα-target genes, including AGR2. This
justifies the multiple correlations we found between FOXA1 and other genes
in non-TNBC. However, in tamoxifen-resistant cells, the expression of AGR2
occurs in a constitutive manner, requiring FOXA1, but loses its dependence
on ER, suggesting a mechanism where changes in FOXA1 activity obviate
the need for ER in the regulation of this gene [64]. It is hypothesized that
AGR2 may be involved in the folding of the extracellular domains of pro-
teins that influence cell growth and survival, and that AGR2 may represent
an important biomarker and therapeutic target in BC [65]. It thus appears
that the FOXA1 -AGR2 link in TNBC may be of particular relevance and
deserves further study.
The fact that the biological role in TNBC of approximately 60% of the
selected genes has been previously reported strengthens our analysis and
fosters investigation on the potential role of the remaining selected genes in
BC and in particular TNBC.
4.4 Conclusion
This work shows that robust sparse logistic regression can be a powerful tool
in precision medicine. It enables accurate prediction of the BC subtype, irre-
spective of the possible presence of outliers situated in either the clinical label
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or in the gene expression data. In contrast, classical sparse logistic regression
methods are severely affected by the outliers in the data. At the same time,
robust methodology allows to inspect the detected outliers which may lead
to the correct status of the patient and the prescription of the appropriate
treatment. Due to the sparse nature of this robust regression, genes included
in the model may be highly relevant to the understanding of TNBC. While
60% of the selected genes were previously reported to be related to TNBC
or BC, the remaining identified genes deserve further attention as potential
biomarkers for the disease. Among the selected genes, biologically relevant
gene networks could be identified both for TNBC and non-TNBC patient
data, particularly the strong FOXA1 -AGR2 link in TNBC. These results
are intended to contribute to BC/TNBC understanding, the definition of
new therapies and ultimately more effective TNBC management.
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